Tailored Cancer Vaccines? NousCom is working on it!

Screenshot 2016 09 29 at 4.53.52 PM e1475160985987

We aren’t leaving Switzerland yet! We took a scenic train to Basel in order to meet nousCom, a very young biotech developing cancer vaccines.

nouscom logoCity: Basel, Switzerland

Founded: 2015

Employees: unknown

Financial Data: €12M raised in series A

Riccardo Cortese
Riccardo Cortese, CEO

Mission: NousCom is a Biotech that develops next generation cancer vaccines with patient- and tumor-specific antigens. Their vaccines combine viruses modified to selectively target tumor antigens and adenoviral vectors for the delivery of cancer antigens.

Comment: The company is getting ready to compete against the big players in immuno-oncology with an expert team, big investors, brand-new GMP labs and innovative science. We expect hearing about positive results very soon. And we like the strong presence of women in their Senior Management Board!

Feature Image Credit: Labiotech Map

Explore other topics: ImmunotherapySwitzerlandVaccines

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.